Sum­mit wins $62M BAR­DA con­tract, shares surge; No­var­tis adds new CGRP da­ta

⇨ Shares of Sum­mit Ther­a­peu­tics $SMMT shot up this morn­ing af­ter the biotech re­port­ed that it had won a $62 mil­lion con­tract from BAR­DA to sup­port its late-stage work on its C. dif­fi­cile in­fec­tion drug ri­dini­la­zole.

⇨ The In­ter­na­tion­al Headache So­ci­ety meet­ing in Van­cou­ver over the week­end proved a good op­por­tu­ni­ty for the lead­ers in the CGRP mi­graine drug race to dis­play their lat­est rounds of pos­i­tive news. No­var­tis re­searchers showed up with a new analy­sis from a piv­otal Phase II study which in­di­cates their drug erenum­ab re­duced month­ly mi­graine days in pa­tients with chron­ic mi­graine for whom pre­vi­ous pre­ven­tive treat­ments have failed. This will help make their case that mi­graine suf­fer­ers who have been dis­ap­point­ed be­fore can have a good shot of suc­cess with their ther­a­py. Pro­fes­sor Mes­soud Ashina of the Dan­ish Headache Cen­ter and de­part­ment of neu­rol­o­gy, Uni­ver­si­ty of Copen­hagen, Den­mark not­ed: ”By sig­nif­i­cant­ly cut­ting mi­graine days, erenum­ab could help peo­ple get back much of their lives, which is what mat­ters most to them.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER